Skip to main content
. 2019 Aug 19;84(4):849–860. doi: 10.1007/s00280-019-03914-2

Fig. 2.

Fig. 2

Scatterplot of Vz (a), CL (b), and t½ (c) following initial 24-h thiotepa IV infusion in pediatric patients with solid tumors or brain tumors and 2-h thiotepa IV infusion in patients with malignant lymphoma (pharmacokinetic analysis population). CL clearance, IV intravenous, t½ biological half-life, Vz volume of distribution